Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Values related to age, height, body weight, TRACP5b, BMD and E2 also significantly differed between NN and LL groups, while age, height, body weight, BMI, Ca, 25(OH)D, TRACP5b, BMD and E2 differed significantly between LN and LL groups (Table 1).

Source: Basic characteristics of study subjects. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Metabolomics-based profiles predictive of low bone mass in menopausal women

Study design awaiting verification · Bone Reports · 2018

Original publication title

Metabolomics-based profiles predictive of low bone mass in menopausal women

Takeshi Miyamoto; Akiyoshi Hirayama; Yuiko Sato; Tami Koboyashi; Eri Katsuyama; Hiroya Kanagawa; Atsuhiro Fujie; Mayu Morita; Ryuichi Watanabe; Toshimi Tando; Kana Miyamoto; Takashi Tsuji; Atsushi Funayama; Tomoyoshi Soga; Masaru Tomita; Masaya Nakamura; Morio Matsumoto

© 2018 The Authors

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis.

To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss.

Highlights

  • •

    Comprehensive metabolomic analysis was undertaken in women with normal or low estradiol and normal or low bone mass.

  • •

    52 metabolites were identified as biomarkers of estrogen deficiency and/or low bone mass.

  • •

    Metabolomic profiling could predict estrogen-deficiency and/or low bone mineral density in postmenopausal women.

Authors’ abstract

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Low bone mass and/or pre-existing bone fragility fractures serve as diagnostic criteria in deciding when to start medication for osteoporosis. Although osteoporosis is a metabolic disorder, metabolic markers to predict reduced bone mass are unknown. Here, we show serum metabolomics profiles of women grouped as pre-menopausal with normal bone mineral density (BMD) (normal estrogen and normal BMD; NN), post-menopausal with normal BMD (low estrogen and normal BMD; LN) or post-menopausal with low BMD (low estrogen and low BMD; LL) using comprehensive metabolomics analysis.

To do so, we enrolled healthy volunteer and osteoporosis patient female subjects, surveyed them with a questionnaire, measured their BMD, and then undertook a comprehensive metabolomics analysis of sera of the three groups named above. We identified 24 metabolites whose levels differed significantly between NN/LN and NN/LL groups, as well as 18 or 10 metabolites whose levels differed significantly between NN/LN and LN/LL, or LN/LL and NN/LN groups, respectively. Our data shows metabolomics changes represent useful markers to predict estrogen deficiency and/or bone loss.

Highlights

  • •

    Comprehensive metabolomic analysis was undertaken in women with normal or low estradiol and normal or low bone mass.

  • •

    52 metabolites were identified as biomarkers of estrogen deficiency and/or low bone mass.

  • •

    Metabolomic profiling could predict estrogen-deficiency and/or low bone mineral density in postmenopausal women.

Publication and source details

Original title: Metabolomics-based profiles predictive of low bone mass in menopausal women

Takeshi Miyamoto; Akiyoshi Hirayama; Yuiko Sato; Tami Koboyashi; Eri Katsuyama; Hiroya Kanagawa; Atsuhiro Fujie; Mayu Morita; Ryuichi Watanabe; Toshimi Tando; Kana Miyamoto; Takashi Tsuji; Atsushi Funayama; Tomoyoshi Soga; Masaru Tomita; Masaya Nakamura; Morio Matsumoto

Bone Reports · 2018

⁎ Corresponding author at: Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan. miyamoto@z5.keio.jp© 2018 The Authors2018https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:06:17.347216+00:00

DOI: 10.1016/j.bonr.2018.06.004 · PMC6019687